Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TTPH
  • CUSIP: N/A
  • Web: www.tphase.com
Capitalization:
  • Market Cap: $334.4 million
  • Outstanding Shares: 51,053,000
Average Prices:
  • 50 Day Moving Avg: $6.31
  • 200 Day Moving Avg: $7.31
  • 52 Week Range: $3.11 - $9.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.54
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $5.01 million
  • Price / Sales: 66.75
  • Book Value: $2.67 per share
  • Price / Book: 2.45
Profitability:
  • EBIDTA: ($104,990,000.00)
  • Net Margins: -2,092.20%
  • Return on Equity: -79.79%
  • Return on Assets: -71.63%
Debt:
  • Current Ratio: 6.12%
  • Quick Ratio: 6.12%
Misc:
  • Average Volume: 1.26 million shs.
  • Beta: 2.59
  • Short Ratio: 0.89
 

Frequently Asked Questions for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.76) by $0.07. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. Tetraphase Pharmaceuticals's revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.47) EPS. View Tetraphase Pharmaceuticals' Earnings History.

When will Tetraphase Pharmaceuticals make its next earnings announcement?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Tetraphase Pharmaceuticals.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

6 brokers have issued twelve-month price objectives for Tetraphase Pharmaceuticals' stock. Their forecasts range from $4.00 to $15.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $11.80 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 3,889,264 shares, an increase of 32.8% from the August 15th total of 2,927,894 shares. Based on an average daily volume of 856,396 shares, the days-to-cover ratio is presently 4.5 days. Approximately 7.7% of the shares of the company are sold short.

Who are some of Tetraphase Pharmaceuticals' key competitors?

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Chairman of the Board of Directors
  • Guy Macdonald, President and Chief Executive Officer, Director
  • Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance
  • Maria D. Stahl, Senior Vice President, General Counsel
  • Patrick T. Horn M.D. Ph.D., Chief Medical Officer
  • Jeffrey A. Chodakewitz M.D., Director
  • Geraldine A. Henwood Ph.D., Director
  • Garen G. Bohlin, Independent Director
  • John G. Freund M.D., Independent Director
  • Nancy J. Wysenski, Independent Director

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Canada Pension Plan Investment Board (4.36%), Vanguard Group Inc. (2.78%), FMR LLC (2.62%), Dimensional Fund Advisors LP (2.16%), Tekla Capital Management LLC (1.97%) and Northern Trust Corp (1.74%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.

Who sold Tetraphase Pharmaceuticals stock? Who is selling Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Vanguard Group Inc., TIAA CREF Investment Management LLC, Russell Investments Group Ltd., FMR LLC, Wells Fargo & Company MN, Nationwide Fund Advisors and Teachers Advisors LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Numeric Investors LLC, EcoR1 Capital LLC, Dimensional Fund Advisors LP, Strs Ohio, State Street Corp, Federated Investors Inc. PA, Northern Trust Corp and Quantitative Investment Management LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $6.55.


MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $11.80 (80.15% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Needham & Company LLCReiterated RatingHoldHighView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$13.00LowView Rating Details
8/28/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$14.00HighView Rating Details
7/26/2017BMO Capital MarketsReiterated RatingOutperform$12.00 -> $13.00HighView Rating Details
7/11/2017HC WainwrightInitiated CoverageBuy -> Buy$15.00HighView Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00N/AView Rating Details
5/16/2016GabelliReiterated RatingNeutralN/AView Rating Details
11/19/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$12.00 -> $21.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Earnings History by Quarter for Tetraphase Pharmaceuticals (NASDAQ TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.63)N/AView Earnings Details
8/2/2017Q2 2017($0.76)($0.83)$1.54 million$1.59 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.60)($0.79)$1.46 million$1.48 millionViewN/AView Earnings Details
3/8/2017Q4($0.60)($0.61)$1.28 million$1.09 millionViewListenView Earnings Details
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)$2.74 million$3.07 millionViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
2017 EPS Consensus Estimate: ($2.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.56)($0.59)
Q2 20172($0.63)($0.58)($0.61)
Q3 20172($0.61)($0.59)($0.60)
Q4 20172($0.53)($0.46)($0.50)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 41.73%
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Jacques DumasInsiderSell17,500$6.00$105,000.00View SEC Filing  
8/17/2017Jacques DumasInsiderSell7,155$5.86$41,928.30View SEC Filing  
3/15/2017L Patrick GageDirectorBuy11,000$7.49$82,390.00View SEC Filing  
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Source:
DateHeadline
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 22 at 7:40 PM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
seekingalpha.com logoTetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst - Seeking Alpha
seekingalpha.com - September 17 at 8:51 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Short Interest Update
www.americanbankingnews.com - September 16 at 1:20 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 15 at 2:32 AM
americanbankingnews.com logoTetraphase Pharmaceuticals' (TTPH) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - September 12 at 11:23 AM
americanbankingnews.com logo$1.46 Million in Sales Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter
www.americanbankingnews.com - September 12 at 1:36 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections
finance.yahoo.com - September 11 at 7:59 AM
americanbankingnews.com logoTetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Earnings of -$0.56 Per Share
www.americanbankingnews.com - September 11 at 12:08 AM
finance.yahoo.com logoTetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - September 5 at 9:32 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - September 2 at 11:16 AM
finance.yahoo.com logoETFs with exposure to Tetraphase Pharmaceuticals, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 10:08 AM
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : August 31, 2017
finance.yahoo.com - August 31 at 11:20 AM
americanbankingnews.com logoZacks Investment Research Lowers Tetraphase Pharmaceuticals, Inc. (TTPH) to Hold
www.americanbankingnews.com - August 30 at 11:36 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - August 28 at 11:20 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Sees Large Increase in Short Interest
www.americanbankingnews.com - August 28 at 1:48 AM
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:54 AM
americanbankingnews.com logo Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million
www.americanbankingnews.com - August 25 at 6:00 AM
americanbankingnews.com logoInsider Selling: Tetraphase Pharmaceuticals, Inc. (TTPH) Insider Sells 17,500 Shares of Stock
www.americanbankingnews.com - August 24 at 7:58 PM
americanbankingnews.com logo-$0.58 EPS Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter
www.americanbankingnews.com - August 23 at 12:20 PM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - August 22 at 12:44 PM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Insider Sells $41,928.30 in Stock
www.americanbankingnews.com - August 21 at 8:10 PM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 21 at 2:26 AM
americanbankingnews.com logoContrasting Tetraphase Pharmaceuticals (TTPH) and Pernix Therapeutics Holdings (PTX)
www.americanbankingnews.com - August 20 at 4:22 PM
streetinsider.com logoTetraphase Pharma (TTPH) Announces Submission and Validation of IV Eravacycline Marketing Authorization ... - StreetInsider.com
www.streetinsider.com - August 18 at 8:11 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
finance.yahoo.com - August 17 at 8:39 AM
zacks.com logoOptions Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock
www.zacks.com - August 16 at 8:28 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 9 at 9:10 AM
americanbankingnews.com logo Analysts Anticipate Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million
www.americanbankingnews.com - August 7 at 9:12 AM
americanbankingnews.com logoEquities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.'s Q3 2017 Earnings (NASDAQ:TTPH)
www.americanbankingnews.com - August 7 at 7:12 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - August 5 at 7:08 AM
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : August 4, 2017
finance.yahoo.com - August 4 at 9:20 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - August 3 at 9:20 PM
finance.yahoo.com logoTetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements
finance.yahoo.com - August 3 at 8:13 AM
finance.yahoo.com logoTetraphase reports 2Q loss
finance.yahoo.com - August 3 at 8:13 AM
finance.yahoo.com logoTetraphase Pharma Decides to Reap Profits With Secondary Offering
finance.yahoo.com - July 29 at 8:05 AM
americanbankingnews.com logoFY2017 Earnings Estimate for Tetraphase Pharmaceuticals, Inc. Issued By Gabelli (TTPH)
www.americanbankingnews.com - July 28 at 11:47 AM
nasdaq.com logoPre-Market Most Active for Jul 28, 2017 : TTPH, BTI, QQQ, SBUX, USLV, TVIX, TEF, WFM, XOM, X, STM, TWTR - Nasdaq
www.nasdaq.com - July 28 at 9:12 AM
seekingalpha.com logoTetraphase Pharmaceuticals: IGNITE4 Data Igniting Share Price - Seeking Alpha
seekingalpha.com - July 28 at 9:12 AM
streetinsider.com logoTetraphase Pharma (TTPH) Prices 10M Shares at $6.50/Sh - StreetInsider.com
www.streetinsider.com - July 28 at 9:12 AM
finance.yahoo.com logoTetraphase Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - July 28 at 9:11 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 27 at 6:42 PM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Earns "Hold" Rating from Needham & Company LLC
www.americanbankingnews.com - July 27 at 5:14 PM
streetinsider.com logoStifel Upgrades Tetraphase Pharmaceuticals (TTPH) to Buy, $15 PT - StreetInsider.com
www.streetinsider.com - July 27 at 8:42 AM
streetinsider.com logoTetraphase Pharma (TTPH) Reports $60M Offering of Common Stock - StreetInsider.com
www.streetinsider.com - July 27 at 8:41 AM
finance.yahoo.com logoHere's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today
finance.yahoo.com - July 27 at 8:41 AM
finance.yahoo.com logoTetraphase Pharmaceuticals Inc (TTPH) Investors Are Parading Today, But Needham Cautious on the Long-Term
finance.yahoo.com - July 27 at 8:41 AM
finance.yahoo.com logoTetraphase Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 27 at 8:41 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Argos Therapeutics and Tetraphase Pharmaceuticals
finance.yahoo.com - July 27 at 8:41 AM
americanbankingnews.com logoTetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - July 26 at 12:29 PM

Social

Chart

Tetraphase Pharmaceuticals (TTPH) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff